120 related articles for article (PubMed ID: 24471873)
1. Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.
Lu T; Goh AW; Yu M; Adams J; Lam F; Teo T; Li P; Noll B; Zhong L; Diab S; Chahrour O; Hu A; Abbas AY; Liu X; Huang S; Sumby CJ; Milne R; Midgley C; Wang S
J Med Chem; 2014 Mar; 57(6):2275-91. PubMed ID: 24471873
[TBL] [Abstract][Full Text] [Related]
2. In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.
Lu T; Laughton CA; Wang S; Bradshaw TD
Mol Pharmacol; 2015 Jan; 87(1):18-30. PubMed ID: 25316768
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents.
Reddy MV; Mallireddigari MR; Cosenza SC; Pallela VR; Iqbal NM; Robell KA; Kang AD; Reddy EP
J Med Chem; 2008 Jan; 51(1):86-100. PubMed ID: 18088089
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors.
Chahrour O; Abdalla A; Lam F; Midgley C; Wang S
Bioorg Med Chem Lett; 2011 May; 21(10):3066-9. PubMed ID: 21463944
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and docking studies of some novel quinoline derivatives bearing a sulfonamide moiety as possible anticancer agents.
Ghorab MM; Ragab FA; Hamed MM
Arzneimittelforschung; 2010; 60(3):141-8. PubMed ID: 20422946
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, structural characterization, and in vitro antitumor activity of novel N-(6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)arylsulfonamides.
Brzozowski Z; Saczewski F; Sławiński J; Bednarski PJ; Grünert R; Gdaniec M
Bioorg Med Chem; 2007 Apr; 15(7):2560-72. PubMed ID: 17306551
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel N-γ-carboline arylsulfonamides as anticancer agents.
Chen J; Liu T; Wu R; Lou J; Cao J; Dong X; Yang B; He Q; Hu Y
Bioorg Med Chem; 2010 Dec; 18(24):8478-84. PubMed ID: 21067933
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.
Lu X; Zhang H; Li X; Chen G; Li QS; Luo Y; Ruan BF; Chen XW; Zhu HL
Bioorg Med Chem; 2011 Nov; 19(22):6827-32. PubMed ID: 22000948
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Schroeder GM; An Y; Cai ZW; Chen XT; Clark C; Cornelius LA; Dai J; Gullo-Brown J; Gupta A; Henley B; Hunt JT; Jeyaseelan R; Kamath A; Kim K; Lippy J; Lombardo LJ; Manne V; Oppenheimer S; Sack JS; Schmidt RJ; Shen G; Stefanski K; Tokarski JS; Trainor GL; Wautlet BS; Wei D; Williams DK; Zhang Y; Zhang Y; Fargnoli J; Borzilleri RM
J Med Chem; 2009 Mar; 52(5):1251-4. PubMed ID: 19260711
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of naphthostyril derivatives as novel protein kinase FGFR1 inhibitors.
Gryshchenko AA; Levchenko KV; Bdzhola VG; Ruban TP; Lukash LL; Yarmoluk SM
J Enzyme Inhib Med Chem; 2015 Feb; 30(1):126-32. PubMed ID: 24939105
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.
Liu Z; Zhou Z; Tian W; Fan X; Xue D; Yu L; Yu Q; Long YQ
ChemMedChem; 2012 Apr; 7(4):680-93. PubMed ID: 22311585
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.
Hirose M; Okaniwa M; Miyazaki T; Imada T; Ohashi T; Tanaka Y; Arita T; Yabuki M; Kawamoto T; Tsutsumi S; Sumita A; Takagi T; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
Bioorg Med Chem; 2012 Sep; 20(18):5600-15. PubMed ID: 22883026
[TBL] [Abstract][Full Text] [Related]
16. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors.
Miyahara S; Miyakoshi H; Yokogawa T; Chong KT; Taguchi J; Muto T; Endoh K; Yano W; Wakasa T; Ueno H; Takao Y; Fujioka A; Hashimoto A; Itou K; Yamamura K; Nomura M; Nagasawa H; Shuto S; Fukuoka M
J Med Chem; 2012 Apr; 55(7):2970-80. PubMed ID: 22339362
[TBL] [Abstract][Full Text] [Related]
19. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Mathieu S; Gradl SN; Ren L; Wen Z; Aliagas I; Gunzner-Toste J; Lee W; Pulk R; Zhao G; Alicke B; Boggs JW; Buckmelter AJ; Choo EF; Dinkel V; Gloor SL; Gould SE; Hansen JD; Hastings G; Hatzivassiliou G; Laird ER; Moreno D; Ran Y; Voegtli WC; Wenglowsky S; Grina J; Rudolph J
J Med Chem; 2012 Mar; 55(6):2869-81. PubMed ID: 22335519
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
